Polycystic Ovarian Syndrome (PCOS) Treatment Market Growth and Recent Trends by 2031

The polycystic ovarian syndrome (PCOS) treatment market forecast helps stakeholders in this marketplace outline their growth strategies. The market is projected to grow from US$ 3.46 billion in 2023 to US$ 5.26 billion by 2031; it is estimated to record a CAGR of 5.4% during 2023–2031.

The increase in the prevalence of PCOS globally, coupled with a significant rise in healthcare spending on PCOS treatment, are the factors that propel polycystic ovarian syndrome (PCOS) treatment market growth. For instance, approximately 6 million women in the US suffer from PCOS, a common hormone imbalance. It raises the risk of several illnesses, such as endometrial cancer, hypertension, type 2 diabetes, infertility, and stroke. Moreover, the Endocrine Society estimates that the diagnosis and treatment of polycystic ovarian syndrome (PCOS), the most prevalent hormone disorder affecting women of reproductive age, will cost US$ 8 billion nationally in 2020.

Developing novel therapeutics will bring new polycystic ovarian syndrome (PCOS) treatment market trends during the forecast period.

Growth Drivers:

Increasing Prevalence of PCOS Among Women Globally Drives Polycystic Ovary Syndrome (PCOS) Treatment Market Growth

Polycystic ovary syndrome (PCOS) is a common multifactorial endocrine disorder among women. According to the World Health Organization (WHO), PCOS affects an estimated 8–13% of women of reproductive age. Globally, PCOS is the most common cause of anovulation and a leading cause of infertility. Also, ~70% of women affected by PCOS remain undiagnosed. Unhealthy lifestyle diet and some environmental factors can cause PCOS. Obesity is a major risk factor for PCOS, as excess body fat can disrupt hormone levels and insulin sensitivity, leading to the development of the condition. With the global obesity epidemic on the rise, more women are at risk of developing PCOS. According to the World Obesity Atlas 2022 by the World Obesity Federation, by 2030, more than one billion people across the world will be affected by obesity, including 1 in every five women.

Furthermore, the increasing prevalence of PCOS has led to a growing demand for effective treatment options. Various pharmaceutical and non-pharmaceutical PCOS treatments are available to regulate hormone levels, improve insulin sensitivity, and address other underlying factors contributing to PCOS. Thus, the rising prevalence of PCOS among women globally drives the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Restraint:

Limited Availability of FDA-Approved Medications Specifically for PCOS Hinders Polycystic Ovarian Syndrome (PCOS) Treatment Market

There is a limited availability of the Food and Drug Administration (FDA)-approved medications specifically designed to address the complex symptoms and underlying hormonal imbalances associated with polycystic ovary syndrome (PCOS). Despite the high prevalence of PCOS and its significant impact on women's health, fertility, and quality of life, there are relatively few pharmaceutical options (off-label drugs) approved by the FDA for the treatment of this condition. The lack of FDA-approved medications presents a challenge for healthcare providers and patients seeking effective and evidence-based PCOS treatments. While off-label use of certain medications such as oral contraceptives, insulin-sensitizing agents, and anti-androgens is common in managing PCOS symptoms, the absence of dedicated therapies limits the ability to address the condition comprehensively. Thus, the limited availability of FDA-approved medications specifically indicated for PCOS restrains the polycystic ovarian syndrome (PCOS) treatment market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Polycystic Ovarian Syndrome (PCOS) Treatment Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The polycystic ovarian syndrome (PCOS) treatment market analysis has been carried out by considering the following segments: product and distribution channel.

By product, the polycystic ovarian syndrome (PCOS) treatment market is segmented into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment held the largest market share in 2023. Further, the clomiphene citrate segment is anticipated to register the highest CAGR during the forecast period. 

The polycystic ovarian syndrome (PCOS) treatment market, by distribution channel, is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest polycystic ovarian syndrome (PCOS) treatment market share in 2023 and is anticipated to register the highest CAGR during the forecast period.

Regional Analysis:

In terms of geography, the scope of the polycystic ovarian syndrome (PCOS) treatment market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held the largest market share. Growing adoption of the latest medical device technologies, rising prevalence of PCOS, and increasing product innovations by key players contribute to the growing polycystic ovarian syndrome (PCOS) treatment market size in North America. According to the US Department of Health & Human Services, PCOS is a common cause of female infertility in the US, which affects ~6% to 12% (~5 million) of US women of reproductive age. According to the study “Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis,” published in July 2023 in the American Journal of Obstetrics and Gynecology, the incidence rate of PCOS in the US is 42.5 cases per 10,000 people every year. Furthermore, various organizations in the country offer comprehensive evaluation, create awareness, and focus on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively engaged in research to study the cause of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness favor the polycystic ovarian syndrome (PCOS) treatment market growth.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Regional Insights

The regional trends and factors influencing the Polycystic Ovarian Syndrome (PCOS) Treatment Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Polycystic Ovarian Syndrome (PCOS) Treatment Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Report Scope

Polycystic Ovarian Syndrome (PCOS) Treatment Market Players Density: Understanding Its Impact on Business Dynamics

The Polycystic Ovarian Syndrome (PCOS) Treatment Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Polycystic Ovarian Syndrome (PCOS) Treatment Market are:

1. Sanofi SA,
2. Merck KGaA,
3. Novartis,
4. Mylan,
5. Takeda Pharmaceutical Company Ltd,
6. Abbott,

Disclaimer: The companies listed above are not ranked in any particular order.

Industry Developments and Future Opportunities:

A few strategic developments by leading players operating in the polycystic ovarian syndrome (PCOS) treatment market, as per the company press releases, are listed below:

• In April 2023, Celmatix launched the Novel PCOS drug program. The company unveiled its most recent therapeutic program, targeting melatonin receptors outside the central nervous system (CNS). The therapeutic medicine will fill a crucial market gap for effective first-line therapies for various women's health conditions, beginning with PCOS and potentially expanding to include endometriosis and menopausal symptoms.
• In January 2022, Celmatix Inc. announced a milestone achievement in its five-year, multi-target alliance with Evotec. Evotec and Bayer AG triggered the milestone to advance a PCOS drug program centered around a novel Celmatix-identified drug target into hit identification.

Competitive Landscape and Key Companies:

Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc are among the prominent companies profiled in the polycystic ovarian syndrome (PCOS) treatment market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.